Page last updated: 2024-09-05

sb 203580 and c.i. 42510

sb 203580 has been researched along with c.i. 42510 in 1 studies

Compound Research Comparison

Studies (sb 203580)	Trials (sb 203580)	Recent Studies (post-2010) (sb 203580)	Studies (c.i. 42510)	Trials (c.i. 42510)	Recent Studies (post-2010) (c.i. 42510)
3,489	4	1,137	4,960	190	1,366

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
He, ZY; Luo, XG; Shang, H; Wang, XH; Xie, X	1

Other Studies

1 other study(ies) available for sb 203580 and c.i. 42510

Article	Year
Inhibiting purinergic P2X7 receptors with the antagonist brilliant blue G is neuroprotective in an intranigral lipopolysaccharide animal model of Parkinson's disease. Molecular medicine reports, 2017, Volume: 15, Issue:2 Topics: Animals; Disease Models, Animal; Dopaminergic Neurons; Imidazoles; Immunohistochemistry; Lipopolysaccharides; Male; Microscopy, Fluorescence; p38 Mitogen-Activated Protein Kinases; Parkinson Disease; Phosphorylation; Protective Agents; Purinergic P2X Receptor Antagonists; Pyridines; Rats; Rats, Sprague-Dawley; Rosaniline Dyes	2017

Article

Year

Inhibiting purinergic P2X7 receptors with the antagonist brilliant blue G is neuroprotective in an intranigral lipopolysaccharide animal model of Parkinson's disease.

Molecular medicine reports, 2017, Volume: 15, Issue:2

Topics: Animals; Disease Models, Animal; Dopaminergic Neurons; Imidazoles; Immunohistochemistry; Lipopolysaccharides; Male; Microscopy, Fluorescence; p38 Mitogen-Activated Protein Kinases; Parkinson Disease; Phosphorylation; Protective Agents; Purinergic P2X Receptor Antagonists; Pyridines; Rats; Rats, Sprague-Dawley; Rosaniline Dyes

2017